Abstract:
B-monoglyceride (B-MG) is a single fatty acyl chain esterified to
the second position of the glycerol backbone and is synthesized from
coconut oil using BIOTECH lipase and n-butyl alcohol. The antimicrobial
activity of B-monoglyceride(B-MG) was tested in vitro and in vivo. The
antimicrobial in vitro test was done to determine the minimum inhibitory
concentration (MIC) and minimum lethal concentration (MLC) of B-MG
against Proteus vulgaris, Enterococcus faecalis, and Candida albicans.
Broth dilution technique was used to determine MIC and MLC, the results
of which were compared with commercially-available antibiotics. A
preliminary in vivo testing was done to demonstrate the potential of B-MG
as treatment for microbial infection. Im vivo test involved dorsal
subcutaneous injection of B-MG on urinary tract infections (UTI) positive
dogs at a dosage of 10 mg/kg daily for five days. The effect of B-MG on
the dogs was evaluated through blood (white blood cell count) and urine
analysis. The MIC was between 10 and 25 ppm for P. vulgaris, between
125 and 150 ppm for E. faecalis, and between 6000 and 8000 ppm for C.
albicans. The MLC was 25 ppm for P. vulgaris, 150 ppm for LE. faecalis,
and 8000 ppm for C. albicans. For P. vulgaris and E. faecalis, there was
100% kill at 25 ppm and 150 ppm B-MG respectively, while 94.70% kill
was the highest value achieved with the use of 500 ppm Amoxicillin and
Co-trimoxazole. B-MG treatment of UTI in dogs caused a decrease in the
indicators of UTI from the urine samples and achieved a 43.65% decrease
in the WBC count. Therefore, B-monoglyceride have confirmed
antimicrobial properties against some microorganisms which can cause
UTI
